Favipiravir
- Generic Name
- Favipiravir
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4FN3O2
- CAS Number
- 259793-96-9
- Unique Ingredient Identifier
- EW5GL2X7E0
- Background
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
- Indication
⑴用于埃博拉病毒感染的治疗。
⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）
- Associated Conditions
- Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza
Efficacy of Favipiravir Against Severe Ebola Virus Disease
- Conditions
- Ebola Virus Disease
- Interventions
- Other: WHO-recommended therapies
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Beijing Institute of Pharmacology and Toxicology
- Target Recruit Count
- 77
- Registration Number
- NCT02662855
Efficacy of Favipiravir Against Ebola (JIKI)
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Target Recruit Count
- 126
- Registration Number
- NCT02329054
- Locations
- 🇬🇳
The caregivers treatment center, Conakry, Guinea
🇬🇳ALIMA Ebola care center, Nzerekore, Guinea
🇬🇳MSF Ebola treatment centre, Gueckedou, Guinea
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316
- First Posted Date
- 2014-01-03
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- MDVI, LLC
- Target Recruit Count
- 860
- Registration Number
- NCT02026349
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- MDVI, LLC
- Target Recruit Count
- 1161
- Registration Number
- NCT02008344
T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- MDVI, LLC
- Target Recruit Count
- 550
- Registration Number
- NCT01728753
- Locations
- 🇺🇸
Miami Research Associates, Miami, Florida, United States
Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- MDVI, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01419457
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- MDVI, LLC
- Target Recruit Count
- 530
- Registration Number
- NCT01068912
- Locations
- 🇺🇸
#048, Elkridge, Maryland, United States
🇺🇸#132, Houston, Texas, United States
🇺🇸#157, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.